Core Viewpoint - The Gross Law Firm is notifying shareholders of Snap Inc. regarding a potential class action lawsuit due to misleading statements about the company's advertising revenue growth, which significantly declined during the reported period [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Snap Inc. provided overly positive statements to investors while concealing material adverse facts about its advertising revenue growth rate, which fell from 9% in Q1 to only 1% in April 2025 [3]. - On August 5, 2025, Snap announced a deceleration in advertising revenue growth, attributing it to issues with its ad platform, the timing of Ramadan, and minor changes [3]. Stock Price Impact - Following the announcement of the financial results on August 5, 2025, Snap's stock price dropped from $9.39 per share to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [3]. Class Action Details - The class period for the lawsuit is defined as April 29, 2025, to August 5, 2025, with a deadline for shareholders to register for the class action set for October 20, 2025 [4]. - Shareholders who register will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Charter Communications, Inc. (NASDAQ: CHTR). Shareholders who purchased shares of CHTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/charter-communications-inc-loss-submission-form/?id=167844&from=3  C ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against AVITA Medical, Inc. for possible violations of federal securities laws and unlawful business practices, particularly related to a significant backlog of unpaid claims affecting the company's financial performance [1][3]. Financial Performance - On August 7, 2025, Avita reported a six-month backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand in the first half of the year [3]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers [3]. - Following the announcement, Avita's stock price fell by $1.13, or approximately 21%, from $5.38 to $4.25 per share [3]. Legal Investigation - The law firm is encouraging investors who suffered losses in Avita to contact them to discuss their legal rights and options [1][4]. - The investigation aims to determine if Avita's actions constituted violations of securities laws, which could have implications for investors [1]. Company Background - AVITA Medical, Inc. is involved in the wound care sector, specifically with its product Recell, which has faced operational challenges due to the backlog of claims [3]. - Bragar Eagel & Squire, P.C. is a recognized law firm that represents investors in complex litigation across various jurisdictions [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Snap Inc. regarding a class action lawsuit due to misleading statements about the company's advertising revenue growth, which significantly declined from 9% to 1% during the specified period [1]. Group 1: Allegations and Financial Impact - The complaint alleges that Snap Inc. provided overly positive statements while concealing material adverse facts about its advertising revenue growth rate [1]. - Snap's advertising revenue growth decelerated, attributed to issues with its ad platform and external factors, leading to a significant stock price drop of approximately 17.15% from $9.39 to $7.78 per share in one day [1]. Group 2: Class Action Details - Shareholders who purchased shares of Snap during the class period from April 29, 2025, to August 5, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 20, 2025 [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to join [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fiserv, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Clover platform and its impact on merchant business [1][3]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv forced merchants using its older Payeezy platform to switch to the Clover platform due to cost issues and other problems [3]. - It is claimed that Clover's revenue growth was artificially inflated by these conversions, masking a slowdown in acquiring new merchants [3]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and inadequate customer service [3]. - As a result of these merchant losses, Clover's growth in Gross Payment Volume (GPV) and revenue was said to be unsustainable and significantly slowing [3]. - The lawsuit asserts that Fiserv's positive statements regarding Clover's growth strategies and business prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as July 24, 2024, to July 22, 2025 [3]. - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiffs [4]. - There is no cost or obligation for shareholders to participate in the case, and they will receive updates through a portfolio monitoring software [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Snap Inc. regarding a class action lawsuit due to misleading statements about the company's advertising revenue growth, which significantly declined during the reported period [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from April 29, 2025, to August 5, 2025 [3]. - Allegations include that Snap's management provided overly positive statements while concealing a significant decline in advertising revenue growth, which dropped from 9% in Q1 to only 1% in April 2025 [3]. Financial Impact - On August 5, 2025, Snap announced a slowdown in advertising revenue growth, attributing it to issues with their ad platform and external factors [3]. - Following this announcement, Snap's stock price fell from $9.39 per share to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by October 20, 2025, to potentially be appointed as lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - The complaint against LifeMD alleges that the company and its executives violated federal securities laws by making misleading statements and failing to disclose critical information regarding their competitive position and customer acquisition costs [2]. Financial Performance - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from the previous guidance of $268 to $275 million [3]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [3]. Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4]. - The law firm Faruqi & Faruqi encourages individuals with information regarding LifeMD's conduct to come forward, including whistleblowers and former employees [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. due to allegations of violations of federal securities laws and unlawful business practices following a negative report on its product Vykat XR [2][3]. Group 1: Company Overview - Soleno Therapeutics, Inc. (NASDAQ: SLNO) is facing scrutiny after a report from Scorpion Capital labeled its only product, Vykat XR, as overpriced and potentially unsafe for children [3]. - Following the report's publication on August 15, 2025, Soleno's stock price dropped by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share [3]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses from Soleno's stock to contact them to discuss their legal rights and options [1][4]. - The law firm is specifically looking into whether Soleno has engaged in unlawful business practices that could have harmed investors [2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices, following a significant drop in stock price after the announcement of clinical trial results for Hyalofast [1][3]. Group 1: Company Overview - Anika Therapeutics, Inc. (NASDAQ: ANIK) is involved in the development of medical products, including Hyalofast, a resorbable hyaluronic acid scaffold for cartilage repair [3]. - The company recently announced topline results from a pivotal clinical trial, which indicated that while Hyalofast showed improvements in treated patients, it did not meet its pre-specified co-primary endpoints [3]. Group 2: Stock Performance - Following the announcement of the clinical trial results, Anika's stock price fell by $3.06 per share, representing a decline of 27.42%, closing at $8.10 per share on July 30, 2025 [3]. Group 3: Legal Investigation - Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses due to the stock price decline to contact them to discuss their legal rights and options [1][4]. - The investigation is focused on whether Anika's actions may have constituted violations of federal securities laws [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of CTO Realty Growth, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its dividends and financial practices during the specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint claims that CTO Realty Growth, Inc. misled investors by stating that its dividends were sustainable, while in reality, they were less sustainable than represented [1] - It is alleged that the company used deceptive practices to inflate its adjusted funds from operations and overstate the profitability of its Ashford Lane property [1] - Consequently, the business and financial prospects of CTO were overstated, leading to materially false and misleading public statements [1] Class Period and Registration - The class period for the allegations spans from February 18, 2021, to June 24, 2025 [1] - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 7, 2025 [2] Firm's Commitment - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to ensure companies adhere to responsible business practices [3]